Atyr PHARMA (NASDAQ:ATYR) Now Covered by Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a report released on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 price objective on the stock.

Several other equities research analysts have also recently commented on the company. Royal Bank of Canada reissued an outperform rating and set a $16.00 target price on shares of Atyr PHARMA in a report on Wednesday, August 14th. HC Wainwright reissued a buy rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Thursday, August 15th.

Atyr PHARMA Trading Up 7.4 %

Shares of NASDAQ ATYR opened at $1.88 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.63 and a current ratio of 7.63. The business’s 50 day simple moving average is $1.87. The firm has a market capitalization of $129.74 million, a P/E ratio of -2.09 and a beta of 1.22. Atyr PHARMA has a 12-month low of $1.08 and a 12-month high of $2.50.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. Sell-side analysts forecast that Atyr PHARMA will post -0.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Atyr PHARMA

In related news, Director Paul Schimmel purchased 52,300 shares of the company’s stock in a transaction on Wednesday, July 24th. The shares were bought at an average price of $1.93 per share, with a total value of $100,939.00. Following the completion of the acquisition, the director now owns 413,023 shares of the company’s stock, valued at $797,134.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.70% of the stock is owned by corporate insiders.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.